Articles related to POLITICS & MEDICINE

Cancer research infrastructure faces its most severe funding crisis in over two decades, with institutions forced to choose between maintaining current studies and preserving workforce capacity for future breakthroughs.

Prior to CDC’s Sickle Cell Data Collection program, the actual number of Americans living with sickle cell disease was unknown, with current estimates of 100,000 patients based on systematic data collection efforts now at risk.

Medicare reimbursement for RPM remains lowest in rural areas where chronic disease prevalence exceeds national averages and provider access presents significant challenges.

FDA officials emphasize that unlike other high-income nations targeting elderly and high-risk populations, the US previously maintained universal vaccination recommendations for all Americans over 6 months, a policy they now consider insufficiently evidence-based.

Research disruption spans 24 institutes with disproportionate impact on minority health disparities and early career investigators.

The preservation of Medicare drug price negotiations alongside the removal of other cost-reduction measures creates a complex landscape for healthcare delivery and patient access.